Oscar Health continues its push higher after getting Barclays upgrade
Oscar Health shares surged Wednesday, fueled by an upgrade from Barclays after the company reiterated its full-year guidance earlier this week.
The stock has rallied lately, up about 40% from its June 3 closing price and pushing to its highest levels since the hype days just after its IPO in March of 2021.
Barclays upgraded the insurer to “overweight” from “equal-weight” and raised its price target to $35 from $30, according to Investing.com. Analysts cited the company’s focused participation in the fast-growing Affordable Care Act market as an avenue for potential growth.
On Monday at a Goldman Sachs healthcare conference, Oscar reassured investors by reaffirming the company’s full-year 2026 financial guidance, according to a company filing.
The recent momentum comes after Oscar reported strong Q1 results in May. The company reported revenue of $4.65 billion, up from $3 billion for the first quarter of 2025, driven by higher membership and rate increases.